GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Guardian Pharmacy Services Inc (NYSE:GRDN) » Definitions » Net Issuance of Preferred Stock

GRDN (Guardian Pharmacy Services) Net Issuance of Preferred Stock : $0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Guardian Pharmacy Services Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Guardian Pharmacy Services's net issuance of preferred for the three months ended in Mar. 2025 was $0 Mil. The number is 0, which means that Guardian Pharmacy Services has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Guardian Pharmacy Services's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2025 was $0 Mil.


Guardian Pharmacy Services Net Issuance of Preferred Stock Historical Data

The historical data trend for Guardian Pharmacy Services's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardian Pharmacy Services Net Issuance of Preferred Stock Chart

Guardian Pharmacy Services Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Preferred Stock
Get a 7-Day Free Trial - - - - -

Guardian Pharmacy Services Quarterly Data
Sep19 Dec19 Mar20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Guardian Pharmacy Services Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardian Pharmacy Services Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Guardian Pharmacy Services's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardian Pharmacy Services Business Description

Traded in Other Exchanges
N/A
Address
300 Galleria Parkway SE, Suite 800, Atlanta, GA, USA, 30339
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.